Poly Medicure Limited (POLYMED) AI Stock Analysis

• Market Cap: ₹132.04B
• Dividend Yield: 0.19%
• Average Volume (3M): 8.86K
• Price to Earnings (P/E): 63.3
• Beta (1Y): 0.81
• Revenue Growth: 12.46%
• EPS Growth: 16.66%
• Country: IN
• Employees: 6,300
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 7.70
• Shares Outstanding: 101,359,490
• 10 Day Avg. Volume: 7,511
• 30 Day Avg. Volume: 8,860
• PEG Ratio: 2.36
• Price to Book (P/B): 7.72
• Price to Sales (P/S): 12.79
• P/FCF Ratio: -235.75
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 36.03
• Revenue Forecast (FY): ₹18.86B

• Rating: 67 Neutral
• Price Target: ₹1,307.00 ▼(-24.17% Downside)
• Action: Downgraded Date: 02/07/26
• Date: Action: Downgraded 02/07/26

The score is supported primarily by strong underlying financial performance (growth, profitability, and low leverage), but is held back by a pronounced technical downtrend and an expensive valuation with a minimal dividend yield.

Positive Factors

Recurring consumable revenue

Poly Medicure sells single-use medical consumables across many hospital departments. That creates durable, repeatable revenue driven by routine procedures and infection-control norms. A broad SKU base and distributor/export channels support predictable reorder streams and cross-selling, strengthening revenue visibility over months.

Negative Factors

Negative free cash flow from heavy capex

Persistent negative free cash flow driven by heavy capex reduces internal liquidity and may require external funding if investment does not rapidly translate into higher operating cash. Over a multi-month horizon, continued capex absorption can constrain flexibility for dividends, buybacks, or opportunistic M&A.

Poly Medicure Limited Business Overview & Revenue Model

Company Description

Poly Medicure Limited manufactures and sells medical devices. It offers infusion devices, such as I.V. cannulas, mid line catheters, arterial cannula, three way stop cocks, I.V. infusion sets, manifolds, safety winged infusion sets, T-type extensi...

Read more

Poly Medicure Limited manufactures and sells medical devices. It offers infusion devices, such as I.V. cannulas, mid line catheters, arterial cannula, three way stop cocks, I.V. infusion sets, manifolds, safety winged infusion sets, T-type extensi...

How the Company Makes Money

Poly Medicure makes money primarily by selling single-use (disposable) medical devices and consumables to healthcare providers and to distribution/export channels. Revenue is generated across multiple product categories such as infusion-related di...

Read more

Poly Medicure makes money primarily by selling single-use (disposable) medical devices and consumables to healthcare providers and to distribution/export channels. Revenue is generated across multiple product categories such as infusion-related di...

Poly Medicure Limited Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	17.12B	16.70B	13.76B	11.15B	9.23B	7.86B
Gross Profit	10.53B	11.11B	8.89B	7.06B	5.72B	5.23B
EBITDA	4.82B	4.52B	3.58B	2.68B	2.12B	2.13B
Net Income	3.62B	3.39B	2.58B	1.79B	1.47B	1.36B
Balance Sheet
Total Assets	35.87B	31.92B	18.59B	15.77B	13.77B	12.24B
Cash, Cash Equivalents and Short-Term Investments	11.06B	12.08B	2.86B	3.01B	3.52B	3.74B
Total Debt	2.40B	1.80B	1.74B	1.49B	1.27B	1.37B
Total Liabilities	6.55B	4.27B	3.89B	3.36B	2.89B	2.58B
Stockholders Equity	29.18B	27.66B	14.70B	12.42B	10.87B	9.66B
Cash Flow
Free Cash Flow	-658.89M	-906.06M	-109.34M	-484.49M	-321.05M	236.01M
Operating Cash Flow	914.43M	2.40B	2.66B	1.91B	1.23B	1.19B
Investing Cash Flow	-1.23B	-11.94B	-2.41B	-1.79B	-853.32M	-4.36B
Financing Cash Flow	492.71M	9.51B	-201.53M	-125.05M	-353.38M	3.17B

Poly Medicure Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1723.55
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:POLYMED, the sentiment is Neutral. The current price of 1723.55 is above the 20-day moving average (MA) of 1287.77, above the 50-day MA of 1401.14, and below the 200-day MA of 1836.68, indicating a neutral trend. The MACD of -41.43 indicates Negative momentum. The RSI at 48.76 is Neutral, neither overbought nor oversold. The STOCH value of 37.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:POLYMED.

Poly Medicure Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ERIS	70 Outperform	₹185.34B	51.42	―	0.47%	20.02%	19.17%
POLYMED	67 Neutral	₹132.04B	63.35	―	0.19%	12.46%	16.66%
GLAXO	63 Neutral	₹393.29B	35.44	―	2.16%	4.17%	41.51%
GLAND	61 Neutral	₹281.55B	27.13	―	1.07%	-1.51%	14.27%
APLLTD	57 Neutral	₹136.47B	31.27	―	1.28%	11.42%	-1.91%
GLENMARK	53 Neutral	₹612.02B	35.61	―	0.24%	30.27%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Poly Medicure Limited Corporate Events